Follow
Florian H. Heidel
Florian H. Heidel
University Medicine Greifswald
Verified email at leibniz-fli.de
Title
Cited by
Cited by
Year
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
JE Cortes, FH Heidel, A Hellmann, W Fiedler, BD Smith, T Robak, ...
Leukemia 33 (2), 379-389, 2019
4902019
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain
F Heidel, FK Solem, F Breitenbuecher, DB Lipka, S Kasper, MH Thiede, ...
Blood 107 (1), 293-300, 2006
3212006
Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML
FH Heidel, L Bullinger, Z Feng, Z Wang, TA Neff, L Stein, D Kalaitzidis, ...
Cell stem cell 10 (4), 412-424, 2012
2722012
Requirement for CDK6 in MLL-rearranged acute myeloid leukemia
T Placke, K Faber, A Nonami, SL Putwain, HR Salih, FH Heidel, A Krämer, ...
Blood, The Journal of the American Society of Hematology 124 (1), 13-23, 2014
2112014
Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms
A Prestipino, AJ Emhardt, K Aumann, D O’Sullivan, SP Gorantla, ...
Science translational medicine 10 (429), eaam7729, 2018
2022018
Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera
A Mullally, C Bruedigam, L Poveromo, FH Heidel, A Purdon, T Vu, ...
Blood, The Journal of the American Society of Hematology 121 (18), 3692-3702, 2013
1762013
Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation
F Perner, C Perner, T Ernst, FH Heidel
Cells 8 (8), 854, 2019
1602019
Defective podocyte insulin signalling through p85-XBP1 promotes ATF6-dependent maladaptive ER-stress response in diabetic nephropathy
T Madhusudhan, H Wang, W Dong, S Ghosh, F Bock, VR Thangapandi, ...
Nature communications 6 (1), 6496, 2015
1602015
Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
F Palandri, M Breccia, M Bonifacio, N Polverelli, EM Elli, G Benevolo, ...
Cancer 126 (6), 1243-1252, 2020
1222020
JAK2-V617F promotes venous thrombosis through β12 integrin activation
B Edelmann, N Gupta, TM Schnoeder, AM Oelschlegel, K Shahzad, ...
The Journal of clinical investigation 128 (10), 4359-4371, 2018
1092018
Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation
S Cocciardi, A Dolnik, S Kapp-Schwoerer, FG Rücker, S Lux, TJ Blätte, ...
Nature Communications 10 (1), 2031, 2019
1082019
Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6
IZ Uras, GJ Walter, R Scheicher, F Bellutti, M Prchal-Murphy, AS Tigan, ...
Blood, The Journal of the American Society of Hematology 127 (23), 2890-2902, 2016
1052016
Biased distribution of chromosomal breakpoints involving the MLL gene in infants versus children and adults with t (4; 11) ALL
M Reichel, E Gillert, S AngermuÈller, JP Hensel, F Heidel, M Lode, T Leis, ...
Oncogene 20 (23), 2900-2907, 2001
1012001
Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms
AK Jayavelu, TM Schnöder, F Perner, C Herzog, A Meiler, ...
Nature 588 (7836), 157-163, 2020
992020
Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies
S Kasper, F Breitenbuecher, F Heidel, S Hoffarth, B Markova, M Schuler, ...
Blood cancer journal 2 (3), e60-e60, 2012
942012
Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy
C Bruedigam, FO Bagger, FH Heidel, CP Kuhn, S Guignes, A Song, ...
Cell stem cell 15 (6), 775-790, 2014
892014
Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune …
F Heidel, DB Lipka, C von Auer, C Huber, I Scharrer, G Hess
Thrombosis and haemostasis 97 (02), 228-233, 2007
832007
NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells
AK Jayavelu, JP Müller, R Bauer, SA Böhmer, J Lässig, S Cerny-Reiterer, ...
Leukemia 30 (2), 473-483, 2016
772016
Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-γ1-driven activation of mTOR/p70S6-kinase pathway
B Markova, C Albers, F Breitenbuecher, JV Melo, TH Brümmendorf, ...
Oncogene 29 (5), 739-751, 2010
742010
Novel bis (1 H-indol-2-yl) methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase
S Mahboobi, A Uecker, A Sellmer, C Cénac, H Höcher, H Pongratz, ...
Journal of medicinal chemistry 49 (11), 3101-3115, 2006
712006
The system can't perform the operation now. Try again later.
Articles 1–20